- Home
- CLIK vs GKOS Comparison
CLIK vs GKOS Comparison
Compare CLIK & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLIK
- GKOS
- Stock Information
- Founded
- CLIK 2017
- GKOS 1998
- Country
- CLIK Hong Kong
- GKOS United States
- Employees
- CLIK N/A
- GKOS N/A
- Industry
- CLIK
- GKOS Medical/Dental Instruments
- Sector
- CLIK
- GKOS Health Care
- Exchange
- CLIK NYSE
- GKOS Nasdaq
- Market Cap
- CLIK N/A
- GKOS 5.1B
- IPO Year
- CLIK 2024
- GKOS 2015
- Fundamental
- Price
- CLIK $0.36
- GKOS $90.26
- Analyst Decision
- CLIK
- GKOS Strong Buy
- Analyst Count
- CLIK 0
- GKOS 13
- Target Price
- CLIK N/A
- GKOS $155.00
- AVG Volume (30 Days)
- CLIK 3.4M
- GKOS 1.0M
- Earning Date
- CLIK 02-14-2025
- GKOS 04-30-2025
- Dividend Yield
- CLIK N/A
- GKOS N/A
- EPS Growth
- CLIK N/A
- GKOS N/A
- EPS
- CLIK 0.07
- GKOS N/A
- Revenue
- CLIK $6,051,074.00
- GKOS $383,481,000.00
- Revenue This Year
- CLIK N/A
- GKOS $27.84
- Revenue Next Year
- CLIK N/A
- GKOS $27.99
- P/E Ratio
- CLIK $5.32
- GKOS N/A
- Revenue Growth
- CLIK 36.12
- GKOS 21.85
- 52 Week Low
- CLIK $0.25
- GKOS $77.91
- 52 Week High
- CLIK $4.39
- GKOS $163.71
- Technical
- Relative Strength Index (RSI)
- CLIK N/A
- GKOS 41.57
- Support Level
- CLIK N/A
- GKOS $86.16
- Resistance Level
- CLIK N/A
- GKOS $94.55
- Average True Range (ATR)
- CLIK 0.00
- GKOS 6.54
- MACD
- CLIK 0.00
- GKOS 1.11
- Stochastic Oscillator
- CLIK 0.00
- GKOS 54.51
About GKOS Glaukos Corporation
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.